Ethan Ritz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ethan Ritz has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
- Ami N. Shah
Division of Pediatric Surgery, Department of Surgery, Rush University Medical Center, Chicago, IL
2 shared publications - Brian Ch Gulack
Rush University Medical Center
2 shared publications David E. Kurlander
Division of Plastic and Reconstructive Surgery, Department of Surgery, Rush University Medical Center, Chicago, IL, USA
2 shared publications- Mary Jo Fidler
Division of Hematology/Oncology/Stem Cell Transplant, RUSH MD Anderson Cancer Center, Chicago, Illinois
2 shared publications Amber K. Virdi
Affiliation Department of Microbial Pathogens and Immunity, Rush University Medical Center, Chicago, IL, United States of America
1 shared publicationAmi N. Shah
Department of Surgery, Division of Pediatric Surgery, Rush University Medical Center, Chicago, Illinois
1 shared publication
Latest Publications
- 23 July 2026
- Published by Elsevier in Journal of Plastic, Reconstructive & Aesthetic Surgery
- Vol. 120, 300-306
Patient demographic differences in patient-reported outcomes of breast reconstruction: A comparative analysis of BREAST-Q
- 23 July 2026
- Published by Elsevier in Journal of Plastic, Reconstructive & Aesthetic Surgery
- Vol. 120, 300-306
Patient demographic differences in patient-reported outcomes of breast reconstruction: A comparative analysis of BREAST-Q
- Open Access
- 12 February 2026
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 35  (4) , 108588
Mechanical thrombectomy and decompressive hemicraniectomy trends for acute ischemic stroke: A nationwide analysis
- 12 February 2026
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 35  (4) , 108588
Open AccessMechanical thrombectomy and decompressive hemicraniectomy trends for acute ischemic stroke: A nationwide analysis
- 30 April 2025
- Published by Springer Nature in Pediatric Surgery International
- Vol. 41  (1) , 1-7
Hypertonic liquids: a potential method for reducing super absorbent polymer bead associated bowel obstructions in children
Purpose Super absorbent polymer (SAP) beads grow in the presence of liquids, leading to a risk of small bowel obstruction (SBO) following ingestion, but there is little data to guide management in children following SAP bead ingestion. We hypothesize that certain hypertonic liquids could limit the growth of the beads and shrink them, potentially serving as a treatment to prevent SBO. Methods Specific hypertonic liquids were identified a priori to be studied including 100% fruit juices, mineral oil, 50% and 100% Gastrografin, Pedialyte, Cola, polyethylene glycol, and Milk of Magnesia. Simulated intestinal fluid was used as a control. SAP bead growth and shrinkage (after 24 h of pre-hydration) were compared using linear regression with log transformation. Results Mineral oil, Gastrografin, and 100% fruit juices were found to be the most effective at preventing bead growth as compared to intestinal fluid for both small and large beads (p < 0.001). 100% fruit juices were found to be the most effective at shrinking pre-hydrated beads (p < 0.001). Conclusion Gastrografin and 100% fruit juices have the potential to limit the growth of and shrink SAP beads following ingestion. Protocols using these liquids following SAP bead ingestion may be beneficial in preventing SBO-related surgery.
- 30 April 2025
- Published by Springer Nature in Pediatric Surgery International
- Vol. 41  (1) , 1-7
Hypertonic liquids: a potential method for reducing super absorbent polymer bead associated bowel obstructions in children
Purpose Super absorbent polymer (SAP) beads grow in the presence of liquids, leading to a risk of small bowel obstruction (SBO) following ingestion, but there is little data to guide management in children following SAP bead ingestion. We hypothesize that certain hypertonic liquids could limit the growth of the beads and shrink them, potentially serving as a treatment to prevent SBO. Methods Specific hypertonic liquids were identified a priori to be studied including 100% fruit juices, mineral oil, 50% and 100% Gastrografin, Pedialyte, Cola, polyethylene glycol, and Milk of Magnesia. Simulated intestinal fluid was used as a control. SAP bead growth and shrinkage (after 24 h of pre-hydration) were compared using linear regression with log transformation. Results Mineral oil, Gastrografin, and 100% fruit juices were found to be the most effective at preventing bead growth as compared to intestinal fluid for both small and large beads (p < 0.001). 100% fruit juices were found to be the most effective at shrinking pre-hydrated beads (p < 0.001). Conclusion Gastrografin and 100% fruit juices have the potential to limit the growth of and shrink SAP beads following ingestion. Protocols using these liquids following SAP bead ingestion may be beneficial in preventing SBO-related surgery.
- 6 September 2024
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 60  (1) , 161898
Cost Analysis of Early vs Delayed Outpatient Repair of Inguinal Hernias in Premature Infants
- 6 September 2024
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 60  (1) , 161898
Cost Analysis of Early vs Delayed Outpatient Repair of Inguinal Hernias in Premature Infants
- Open Access
- 1 February 2024
- Published by Elmer Press, Inc. in Journal of Endocrinology and Metabolism
- Vol. 14  (1) , 1-12
Associations Between Type 2 Diabetes Subtypes and Complications: Analysis of the Malaysia National Diabetes Registry
Associations Between Type 2 Diabetes Subtypes and Complications: Analysis of the Malaysia National Diabetes Registry
- 1 February 2024
- Published by Elmer Press, Inc. in Journal of Endocrinology and Metabolism
- Vol. 14  (1) , 1-12
Open AccessAssociations Between Type 2 Diabetes Subtypes and Complications: Analysis of the Malaysia National Diabetes Registry
Associations Between Type 2 Diabetes Subtypes and Complications: Analysis of the Malaysia National Diabetes Registry
- Open Access
- 26 April 2023
- Published by Wolters Kluwer Health in Plastic and Reconstructive Surgery - Global Open
- Vol. 11  (4S) , 122
D126. A DIEP Dive into Patient Risk Factors for Hernia and Bulge Development: A Meta-regression
- 26 April 2023
- Published by Wolters Kluwer Health in Plastic and Reconstructive Surgery - Global Open
- Vol. 11  (4S) , 122
Open AccessD126. A DIEP Dive into Patient Risk Factors for Hernia and Bulge Development: A Meta-regression
- 1 August 2021
- Published by Elsevier in Journal of Surgical Research
- Vol. 264, 362-367
Outcomes of Laparoscopic Versus Open Resection of Meckel's Diverticulum
- 1 August 2021
- Published by Elsevier in Journal of Surgical Research
- Vol. 264, 362-367
Outcomes of Laparoscopic Versus Open Resection of Meckel's Diverticulum
- Open Access
Neutrophil-to-Lymphocyte Ratio Is a Predictive Biomarker in Patients with Epidermal Growth Factor Receptor (EGFR) Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Tyrosine Kinase Inhibitor (TKI) Therapy
Background: First-line treatment for patients with non-small cell lung cancer (NSCLC) with a sensitizing epidermal growth factor receptor (EGFR) mutation is a tyrosine kinase inhibitor (TKI). Despite higher response rates and prolonged progression free survival (PFS) compared with platinum doublet chemotherapy, a subset of these patients do not receive prolonged benefit from these agents. We investigate if the neutrophil-to-lymphocyte ratio (NLR) and other markers of cachexia and chronic inflammation correlate with worse outcomes in these patients. Methods: This study is a retrospective review of 137 patients with advanced EGFR-mutated NSCLC treated with TKIs at Rush University Medical Center and University of Chicago Medicine from August 2011 to July 2019, with outcomes followed through July 2020. The predictive value of NLR and body mass index (BMI) was assessed at the start of therapy, and after 6 and 12 weeks of treatment by univariable and multivariable analyses. Results: On univariable analysis, NLR ≥ 5 or higher NLR on a continuous scale were both associated with significantly worse PFS and overall survival (OS) at treatment initiation, and after 6 or 12 weeks of treatment. On multivariable analysis, NLR ≥ 5 was associated with increased risk of death at 12 weeks of therapy (HR 3.002, 95% CI 1.282–7.029, p = 0.011), as was higher NLR on a continuous scale (HR 1.231, 95% CI 1.063–1.425, p = 0.0054). There was no difference in PFS and OS and amongst BMI categories though number of disease sites and Eastern Cooperative Oncology Group (ECOG) performance status was associated with worse PFS and OS. Conclusions: Patients with NLR ≥ 5 have a worse median PFS and median OS than patients with NLR < 5. NLR may have value as a predictive biomarker and may be useful for selecting patients for therapy intensification in the front-line setting either at diagnosis or after 12 weeks on therapy. NLR needs to be validated prospectively.
Open AccessNeutrophil-to-Lymphocyte Ratio Is a Predictive Biomarker in Patients with Epidermal Growth Factor Receptor (EGFR) Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Tyrosine Kinase Inhibitor (TKI) Therapy
Background: First-line treatment for patients with non-small cell lung cancer (NSCLC) with a sensitizing epidermal growth factor receptor (EGFR) mutation is a tyrosine kinase inhibitor (TKI). Despite higher response rates and prolonged progression free survival (PFS) compared with platinum doublet chemotherapy, a subset of these patients do not receive prolonged benefit from these agents. We investigate if the neutrophil-to-lymphocyte ratio (NLR) and other markers of cachexia and chronic inflammation correlate with worse outcomes in these patients. Methods: This study is a retrospective review of 137 patients with advanced EGFR-mutated NSCLC treated with TKIs at Rush University Medical Center and University of Chicago Medicine from August 2011 to July 2019, with outcomes followed through July 2020. The predictive value of NLR and body mass index (BMI) was assessed at the start of therapy, and after 6 and 12 weeks of treatment by univariable and multivariable analyses. Results: On univariable analysis, NLR ≥ 5 or higher NLR on a continuous scale were both associated with significantly worse PFS and overall survival (OS) at treatment initiation, and after 6 or 12 weeks of treatment. On multivariable analysis, NLR ≥ 5 was associated with increased risk of death at 12 weeks of therapy (HR 3.002, 95% CI 1.282–7.029, p = 0.011), as was higher NLR on a continuous scale (HR 1.231, 95% CI 1.063–1.425, p = 0.0054). There was no difference in PFS and OS and amongst BMI categories though number of disease sites and Eastern Cooperative Oncology Group (ECOG) performance status was associated with worse PFS and OS. Conclusions: Patients with NLR ≥ 5 have a worse median PFS and median OS than patients with NLR < 5. NLR may have value as a predictive biomarker and may be useful for selecting patients for therapy intensification in the front-line setting either at diagnosis or after 12 weeks on therapy. NLR needs to be validated prospectively.
- Open Access
- 22 September 2020
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15  (9) , e0239157
CD32 is enriched on CD4dimCD8bright T cells
CD4dimCD8bright T cells, a genuine population of CD8+ T cells, are highly activated and cytolytic. Recently, the low affinity IgG Fc fragment receptor CD32a was described as marker of HIV latency while others reported that CD32a is associated with T cell activation. Given that we have previously established that CD4dimCD8bright T cells are highly activated, mediate anti-HIV responses, and are infected by HIV, we assessed here CD32 expression on CD4dimCD8bright T cells in context of HIV. CD32 frequency on peripheral CD4dimCD8bright and CD4+ T cells was determined by flow cytometry among HIV negative and HIV positive patients. We report that among HIV- individuals, mean CD32 percent expression was 60% on CD4dimCD8bright T cells and 17% on CD4+ T cells (p+ patients, mean CD32 percent expression was 54% on CD4dimCD8bright T cells and 12% on CD4+ T cells (pdimCD8bright T cells did not correlate with CD4 count and viral load and was not different by HIV serostatus. CD32 was also higher on other double positive T cell populations in both HIV negative and HIV positive donors in comparison to their single positive T cell counterpart. Together, these studies indicate that CD32 is enriched on double positive T cells regardless of HIV serostatus. The functional role of CD32 on these double positive T cells remains to be elucidated.
- 22 September 2020
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15  (9) , e0239157
Open AccessCD32 is enriched on CD4dimCD8bright T cells
CD4dimCD8bright T cells, a genuine population of CD8+ T cells, are highly activated and cytolytic. Recently, the low affinity IgG Fc fragment receptor CD32a was described as marker of HIV latency while others reported that CD32a is associated with T cell activation. Given that we have previously established that CD4dimCD8bright T cells are highly activated, mediate anti-HIV responses, and are infected by HIV, we assessed here CD32 expression on CD4dimCD8bright T cells in context of HIV. CD32 frequency on peripheral CD4dimCD8bright and CD4+ T cells was determined by flow cytometry among HIV negative and HIV positive patients. We report that among HIV- individuals, mean CD32 percent expression was 60% on CD4dimCD8bright T cells and 17% on CD4+ T cells (p+ patients, mean CD32 percent expression was 54% on CD4dimCD8bright T cells and 12% on CD4+ T cells (pdimCD8bright T cells did not correlate with CD4 count and viral load and was not different by HIV serostatus. CD32 was also higher on other double positive T cell populations in both HIV negative and HIV positive donors in comparison to their single positive T cell counterpart. Together, these studies indicate that CD32 is enriched on double positive T cells regardless of HIV serostatus. The functional role of CD32 on these double positive T cells remains to be elucidated.
- 1 September 2019
- Published by Elsevier in American Journal of Otolaryngology
- Vol. 40  (5) , 626-630
Heterogeneity in the clinical presentation, diagnosis, and treatment initiation of p16-positive oropharyngeal cancer
- 1 September 2019
- Published by Elsevier in American Journal of Otolaryngology
- Vol. 40  (5) , 626-630
Heterogeneity in the clinical presentation, diagnosis, and treatment initiation of p16-positive oropharyngeal cancer